The innovation of CD44 and CD133 antibody-conjugated ATRA-loaded poly (lactide-co-glycolide)-lecithin-PEG NPs could specifically target CD44+ and CD133+ gastric CSCs, leading to the inhibition of tumor growth. This evidence concerns the gene PROM1 and neoplasm.